Today's pharma briefing: Legal clash over drug testing and a new cancer therapy
The FDA approved a Bristol Myers Squibb oral treatment for advanced multiple myeloma, introducing a new drug class for the blood cancer. The approval was among several developments covered in the Pharmalittle roundup.
Related stories
FDA grants accelerated approval to Bristol Myers Squibb's iberdomide for relapsed multiple myeloma · Cancer research
Regeneron secures approval for ultra-rare bone disorder drug · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more.” Browse more stories.